We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.675 | 4.36 | 4.99 | - | 38,838 | 08:00:27 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.53 | 9.41M |
Date | Subject | Author | Discuss |
---|---|---|---|
02/4/2020 08:47 | I so hurt I have been filtered. You obviously cannot deal with someone that you cannot ban and who is tolerant and democratic. At the end of the day I am here for one reason and one reason only to make money that is why I hold SNG and a fair chunk of them as well. | vitec | |
02/4/2020 08:44 | Vitec ....it was fake news... don't you understand? | kop202 | |
02/4/2020 08:44 | Vitec filtered. | arpy2 | |
02/4/2020 08:37 | What would have happened is that he would have kept on dredging up whatever dubious information he could find which at best would have been only vaguely relevant. He is an insidious if educated individual. His motives were not to save us all I can assure you. | nobbygnome | |
02/4/2020 08:30 | Banning dissenters, those that post alternative views can be counter productive. Strength of opinion and argument should be borne out be the evidence presented. If SNG001 is so good (i believe it is) the evidence will speak for itself and destroy any alternative view that differs. | vitec | |
02/4/2020 08:28 | Yes he was a troll of mine albeit subtle one who is actually quite well informed. But I know his game so better to nip it in the bud! | nobbygnome | |
02/4/2020 08:23 | Yes I think this banning thing really seems to be getting at some . There 's a new thread completely devoted to sour grapes, of such, which shows it's working. Chuckle. | hazl | |
02/4/2020 08:17 | A grudge poster against Nobby for some of Nobby's home truths on IMM. Best ignored. | jev1 | |
02/4/2020 08:11 | Bell end godd bye | jrlomax | |
02/4/2020 08:07 | Why are you copy and pasting things that are ten years old and completely irrelevant to today's product , we're you born a idiot or just woke up like it .,............. | tialouise | |
02/4/2020 08:06 | Think you need to carry on reading the Company news releases rather than stopping at 2012. Not sure if you have noticed they are dosing patients in NHS wards with SNG-001 now. | talk2dubya | |
02/4/2020 08:03 | Anyone have a detailed analytical view on this previous Synairgen SNG-001 FAILED clinical trial? ... IFN-β treatment had no significant effect on this primary endpoint ... ClinicalTrials.gov Identifier: NCT01126177 Recruitment Status : Completed First Posted : May 19, 2010 Last Update Posted : February 13, 2012 Sponsor: Synairgen Research Ltd Study Design Go to sections Study Type : Interventional (Clinical Trial) Actual Enrollment : 300 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: A Randomised, Double-blind, Placebo-controlled Phase II Study, Comparing the Efficacy and Safety of Inhaled SNG001 to Placebo Administered to Asthmatic Subjects After the Onset of a Respiratory Viral Infection for the Prevention or Attenuation of Asthma Symptoms Caused by Respiratory Viruses Study Start Date : March 2010 Actual Primary Completion Date : October 2011 Actual Study Completion Date : January 2012 Am J Respir Crit Care Med. 2014 Jul 15;190(2):145-54. doi: 10.1164/rccm.201312- The effect of inhaled IFN-β on worsening of asthma symptoms caused by viral infections. A randomized trial. Djukanović R1, Harrison T, Johnston SL, Gabbay F, Wark P, Thomson NC, Niven R, Singh D, Reddel HK, Davies DE, Marsden R, Boxall C, Dudley S, Plagnol V, Holgate ST, Monk P; INTERCIA Study Group. Collaborators (28) Author information Abstract RATIONALE: Ex vivo, bronchial epithelial cells from people with asthma are more susceptible to rhinovirus infection caused by deficient induction of the antiviral protein, IFN-β. Exogenous IFN-β restores antiviral activity. OBJECTIVES: To compare the efficacy and safety of inhaled IFN-β with placebo administered to people with asthma after onset of cold symptoms to prevent or attenuate asthma symptoms caused by respiratory viruses. METHODS: A total of 147 people with asthma on inhaled corticosteroids (British Thoracic Society Steps 2-5), with a history of virus-associated exacerbations, were randomized to 14-day treatment with inhaled IFN-β (n = 72) or placebo (n = 75) within 24 hours of developing cold symptoms and were assessed clinically, with relevant samples collected to assess virus infection and antiviral responses. MEASUREMENTS AND MAIN RESULTS: A total of 91% of randomized patients developed a defined cold. In this modified intention-to-treat population, asthma symptoms did not get clinically significantly worse (mean change in six-item Asthma Control Questionnaire <0.5) and IFN-β treatment had no significant effect on this primary endpoint, although it enhanced morning peak expiratory flow recovery (P = 0.033), reduced the need for additional treatment, and boosted innate immunity as assessed by blood and sputum biomarkers. In an exploratory analysis of the subset of more difficult-to-treat, Step 4-5 people with asthma (n = 27 IFN-β; n = 31 placebo), Asthma Control Questionnaire-6 increased significantly on placebo; this was prevented by IFN-β (P = 0.004). CONCLUSIONS: Although the trial did not meet its primary endpoint, it suggests that inhaled IFN-β is a potential treatment for virus-induced deteriorations of asthma in difficult-to-treat people with asthma and supports the need for further, adequately powered, trials in this population. Clinical trial registered with www.clinicaltrials.g Edit: I may be late to the party and not found the previous responses but is that a reason to provide a go away answer? I thought you wanted a range of information on this thread Nobby. You seem to prefer to surround yourself with sycophants. I do not “troll” anyone on ADFN, or anywhere else for that matter, I challenge anyone to find a single instance. | borromini1 | |
02/4/2020 08:00 | Also makes it feel real seeing a respiratory nurse talking (and clearly being excited) about it. Shares run on sentiment if nothing else, SNG are front and centre of this fight all good stuff. | talk2dubya | |
02/4/2020 07:58 | I think it shows that recruiting the 100 patients quickly will be no issue once all the sites are up and running! | nobbygnome | |
02/4/2020 07:58 | Opening with quite a spread this morning 7.9%, that will be a costly buy or sell | makendon | |
02/4/2020 07:56 | Here you are with full credit to oby_1 who sent it to me. | nobbygnome | |
02/4/2020 07:54 | Treated as in made better or dosed? | talk2dubya | |
02/4/2020 07:54 | I want to let the person who discovered it post it.... | nobbygnome | |
02/4/2020 07:52 | “I am hearing some rumours that quite a few patients have already been treated in Southampton. I will let the person who discovered it post the evidence...” Come on then, let’s hear the evidence... | 74tom | |
02/4/2020 07:47 | The time they spend in hospital is also key when there is a bed shortage. Of course some will be treated at home but I suspect most won't. | nobbygnome |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions